Safety and heart rate changes in Covid-19 patients treated with Remdesivir
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir. Methods: We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration. R...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/39c9125592a04ec09ad027f4df134c28 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:39c9125592a04ec09ad027f4df134c28 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:39c9125592a04ec09ad027f4df134c282021-11-30T04:14:18ZSafety and heart rate changes in Covid-19 patients treated with Remdesivir1201-971210.1016/j.ijid.2021.09.036https://doaj.org/article/39c9125592a04ec09ad027f4df134c282021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007414https://doaj.org/toc/1201-9712Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir. Methods: We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration. Results: Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; however, no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). By multivariate analysis, a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration. Conclusions: Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities.Natale Daniele Brunetti, MD, PhDMariacristina Poliseno, MDIrene Francesca Bottalico, MDAntonio Centola, MDLaura Montemurro, MDSalvatore Sica, MDTeresa Santantonio, MDSergio Lo Caputo, MDElsevierarticleRemdesivirCovid-19Cardiovascular ToxicityHeart RateInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 254-257 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Remdesivir Covid-19 Cardiovascular Toxicity Heart Rate Infectious and parasitic diseases RC109-216 |
| spellingShingle |
Remdesivir Covid-19 Cardiovascular Toxicity Heart Rate Infectious and parasitic diseases RC109-216 Natale Daniele Brunetti, MD, PhD Mariacristina Poliseno, MD Irene Francesca Bottalico, MD Antonio Centola, MD Laura Montemurro, MD Salvatore Sica, MD Teresa Santantonio, MD Sergio Lo Caputo, MD Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| description |
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir. Methods: We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration. Results: Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; however, no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). By multivariate analysis, a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration. Conclusions: Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities. |
| format |
article |
| author |
Natale Daniele Brunetti, MD, PhD Mariacristina Poliseno, MD Irene Francesca Bottalico, MD Antonio Centola, MD Laura Montemurro, MD Salvatore Sica, MD Teresa Santantonio, MD Sergio Lo Caputo, MD |
| author_facet |
Natale Daniele Brunetti, MD, PhD Mariacristina Poliseno, MD Irene Francesca Bottalico, MD Antonio Centola, MD Laura Montemurro, MD Salvatore Sica, MD Teresa Santantonio, MD Sergio Lo Caputo, MD |
| author_sort |
Natale Daniele Brunetti, MD, PhD |
| title |
Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| title_short |
Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| title_full |
Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| title_fullStr |
Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| title_full_unstemmed |
Safety and heart rate changes in Covid-19 patients treated with Remdesivir |
| title_sort |
safety and heart rate changes in covid-19 patients treated with remdesivir |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/39c9125592a04ec09ad027f4df134c28 |
| work_keys_str_mv |
AT nataledanielebrunettimdphd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT mariacristinapolisenomd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT irenefrancescabottalicomd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT antoniocentolamd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT lauramontemurromd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT salvatoresicamd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT teresasantantoniomd safetyandheartratechangesincovid19patientstreatedwithremdesivir AT sergiolocaputomd safetyandheartratechangesincovid19patientstreatedwithremdesivir |
| _version_ |
1718406796463308800 |